Replimune Announces FDA Acceptance of RP1 Resubmission for Advanced Melanoma

The FDA accepted the resubmission of the RP1 Biologics License Application for advanced melanoma, with a decision expected by August 2026. This regulatory milestone signals significant progress toward potential approval for this combination therapy.